Tempest Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Tempest Therapeutics (TPST).

Price Target Range — 8 Quarters

Analyst Consensus — 4 Analysts

3Buy

1Hold

Consensus RatingBuy# Analysts4Avg. Consensus PT$27Upside to Avg. PT+5488.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$11→$7
Jan 22, 2026	HC Wainwright & Co.	Joseph Pantginis	Upgrade	Neutral→Buy	$11
Apr 10, 2025	Scotiabank	George Farmer	Downgrade	Sector Outperform→Sector Perform	$91→$9
Apr 10, 2025	HC Wainwright & Co.	Joseph Pantginis	Downgrade	Buy→Neutral	$16
Mar 28, 2025	Scotiabank	George Farmer	PT Cut	Sector Outperform	$169→$91
Mar 28, 2025	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$611→$208
Nov 13, 2024	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$104→$65
Nov 13, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$611
Oct 10, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$611
Aug 15, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$611
Jun 21, 2024	Piper Sandler	Edward Tenthoff	Maintained	Overweight	$104
Jun 20, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$611
May 13, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$611
May 10, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$611
Mar 20, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$611
Mar 14, 2024	Scotiabank	George Farmer	Initiate	Sector Outperform	$169
Mar 13, 2024	Scotiabank	George Farmer	Initiate	Sector Outperform	$169
Mar 12, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$611
Feb 8, 2024	Jefferies	Maury Raycroft	Initiate	Buy	$195

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7

HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the price target from $11 to $7.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Upgrades Tempest Therapeutics to Buy, Announces $11 Price Target

HC Wainwright & Co. analyst Joseph Pantginis upgrades Tempest Therapeutics (NASDAQ:TPST) from Neutral to Buy and announces $11 price target.

Benzinga Newsdesk

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.

Vandana Singh

PRO
Correction : Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Raises Price Target to $9 (Previous Target changed)

Correction: Scotiabank analyst George Farmer downgrades Tempest Therapeutics (NASDAQ:TPST) from Sector Outperform to Sector Perform and raises the price target from $7 to $9. (Previous Target changed)

Benzinga Newsdesk

PRO
HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16

HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics (NASDAQ:TPST) from Buy to Neutral and maintains the price target from $16 to $16.

Benzinga Newsdesk

PRO
Scotiabank Maintains Sector Outperform on Tempest Therapeutics, Lowers Price Target to $7

Scotiabank analyst George Farmer maintains Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform and lowers the price target from $13 to $7.

Benzinga Newsdesk

Tempest Therapeutics Inc

Tempest Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7

PRO
HC Wainwright & Co. Upgrades Tempest Therapeutics to Buy, Announces $11 Price Target

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success

PRO
Correction : Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Raises Price Target to $9 (Previous Target changed)

PRO
HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16

PRO
Scotiabank Maintains Sector Outperform on Tempest Therapeutics, Lowers Price Target to $7

People Also Watch

People Also Watch

Tempest Therapeutics Inc

Tempest Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7

PROHC Wainwright & Co. Upgrades Tempest Therapeutics to Buy, Announces $11 Price Target

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success

PROCorrection : Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Raises Price Target to $9 (Previous Target changed)

PROHC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16

PROScotiabank Maintains Sector Outperform on Tempest Therapeutics, Lowers Price Target to $7

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7

PRO
HC Wainwright & Co. Upgrades Tempest Therapeutics to Buy, Announces $11 Price Target

PRO
Correction : Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Raises Price Target to $9 (Previous Target changed)

PRO
HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16

PRO
Scotiabank Maintains Sector Outperform on Tempest Therapeutics, Lowers Price Target to $7